Cover Image
市場調查報告書

鼻竇炎:開發平台分析

Sinusitis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 232858
出版日期 內容資訊 英文 93 Pages
訂單完成後即時交付
價格
Back to Top
鼻竇炎:開發平台分析 Sinusitis - Pipeline Review, H2 2016
出版日期: 2016年09月14日 內容資訊: 英文 93 Pages
簡介

所謂鼻竇炎是指鼻子的發炎,一般是病毒或是細菌感染引起的,也有可能是過敏引起。症狀有鼻塞、疼痛、壓痛、嗅覺障礙、口臭、咳嗽、牙痛、頭痛、頰骨痛等。危險因子有氣喘、鼻腔異常、HIV/AIDS和囊狀纖維化症等免疫系障礙、過敏等。

本報告提供鼻竇炎的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊,再加上最新的新聞和發表等資訊。

簡介

  • 調查範圍

鼻竇炎 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的開發企業

  • Amgen Inc.
  • F. Hoffmann-La Roche Ltd.
  • Knopp Biosciences LLC
  • Myelo Therapeutics GmbH
  • Regeneron Pharmaceuticals, Inc.
  • Zambon Company S.p.A.

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • AMG-282
  • CG-201
  • dexpramipexole dihydrochloride
  • dupilumab
  • Myelo-001
  • omalizumab
  • ZP-031

最近的開發平台趨勢

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8446IDB

Summary

Global Markets Direct's, 'Sinusitis - Pipeline Review, H2 2016', provides an overview of the Sinusitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Sinusitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sinusitis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Sinusitis
  • The report reviews pipeline therapeutics for Sinusitis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Sinusitis therapeutics and enlists all their major and minor projects
  • The report assesses Sinusitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Sinusitis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Sinusitis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Sinusitis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Sinusitis Overview
  • Therapeutics Development
    • Pipeline Products for Sinusitis - Overview
  • Sinusitis - Therapeutics under Development by Companies
  • Sinusitis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Sinusitis - Products under Development by Companies
  • Sinusitis - Companies Involved in Therapeutics Development
    • AmpliPhi Biosciences Corporation
    • F. Hoffmann-La Roche Ltd.
    • Knopp Biosciences LLC
    • Kyorin Pharmaceutical Co., Ltd.
    • Kyowa Hakko Kirin Co., Ltd.
    • Merck & Co., Inc.
    • Oticpharma Ltd
    • Paratek Pharmaceuticals, Inc.
    • Pfizer Inc.
    • Quorum Innovations LLC
    • Regeneron Pharmaceuticals Inc
    • Therabron Therapeutics, Inc.
  • Sinusitis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ABSA-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • benralizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CG-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dexpramipexole dihydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dupilumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fluticasone propionate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KRPAM-1977X - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • omadacycline tosylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • omalizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • P-008 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PCL-1404 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PF-06817024 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Qi-117 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RG-6149 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Sinusitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Soluble Epoxide Hydrolase for Sinusitis and Allergic Rhinitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Chronic Rhinosinusitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • solithromycin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Sinusitis - Dormant Projects
  • Sinusitis - Product Development Milestones
    • Featured News & Press Releases
      • Aug 09, 2016: AmpliPhi Biosciences Confirms Clinical Trial Progress
      • Aug 03, 2016: AmpliPhi Biosciences Completes Enrollment of Its Investigational Phage Therapy Trial Targeting Staphylococcus aureus
      • Apr 20, 2016: AmpliPhi Biosciences Provides Update on Phase I Trial: Phage Therapy Well Tolerated in First Cohort
      • Feb 03, 2016: Nasal polyps can be treated with medicine dupilumab
      • Feb 02, 2016: Sanofi and Regeneron Announce Publication of Positive Phase 2 Dupilumab Data in the Journal of the American Medical Association
      • Jan 20, 2016: AmpliPhi Biosciences Announces Dosing of First Patient in Phase 1 Clinical Trial of AB-SA01
      • Nov 19, 2015: AmpliPhi Signs Clinical Trial Agreement with University of Adelaide to Conduct a Phase I Trial of Bacteriophage Therapy for Treating Staphylococcus aureus Infections
      • Jun 23, 2015: Jubilant Life Sciences receives ANDA approval for Levofloxacin Tablets
      • Sep 30, 2014: Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Sinusitis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Sinusitis - Pipeline by AmpliPhi Biosciences Corporation, H2 2016
  • Sinusitis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Sinusitis - Pipeline by Knopp Biosciences LLC, H2 2016
  • Sinusitis - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016
  • Sinusitis - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2016
  • Sinusitis - Pipeline by Merck & Co., Inc., H2 2016
  • Sinusitis - Pipeline by Oticpharma Ltd, H2 2016
  • Sinusitis - Pipeline by Paratek Pharmaceuticals, Inc., H2 2016
  • Sinusitis - Pipeline by Pfizer Inc., H2 2016
  • Sinusitis - Pipeline by Quorum Innovations LLC, H2 2016
  • Sinusitis - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016
  • Sinusitis - Pipeline by Therabron Therapeutics, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Sinusitis - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Sinusitis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top